Best Genomics Companies in Capital Region of Denmark, Denmark
The 38 best Genomics companies in Capital Region of Denmark, Denmark in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Santaris Pharma.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Capital Region of Denmark
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Santaris Pharma Developer of RNA-targeted therapies for infectious and metabolic diseases | $104M | 170 mo ago | 60 | Peter Sondermann Founder & CEO | Acquired | — | 512 patents Antisense oligonucleotide therapeutics targeting miRNAs and splice‑switching of TNF receptors | — |
| 2 | SNIPR Biome Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely | $54M | 13 mo ago | 48 48 → 46 (-4%) | Morten Sommer Co-Founder | Series B | — | 142 patents Microbial therapeutics and engineered gene delivery vectors for targeted cell treatments. | 1 job opening |
| 3 | ViroGates Developer of biomarkers and diagnostic kits | $28M | 49 mo ago | 9 | Jakob Knudsen CEO | Series B | WordPressMySQLPHP+30 | 11 patents Digital health risk assessment tools for infectious disease patient triage and monitoring | 1 partnership |
| 4 | Exiqon Develops LNA-based tools for diagnostics and research | $23M | 129 mo ago | 65 | — | Acquired | — | 186 patents MicroRNA biomarker detection and quantification assays for cancer diagnostics | — |
| 5 | BluSense Diagnostics Developer of a next-generation diagnostics platform to diagnose infectious diseases | $14M | 79 mo ago | 35 | — | Deadpooled | — | 5 patents Centrifugal microfluidic platforms for point‑of‑care biochemical analysis and diagnostics | — |
| 6 | Samplix ApS Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells | $13M | 41 mo ago | 26 26 → 31 (+19%) | Marie Mikkelsen Co-founder & CTO | Series A | SalesforceWindows ServerMicrosoft ASP.NET+12 | 65 patents Microfluidic droplet generation, fluorosurfactant stabilization, and particle/DNA sorting technologies. | — |
| 7 | Nuevolution Developer of drug treatments for oncology and chronic inflammatory diseases | $12M | 170 mo ago | 40 | — | Acquired | — | 335 patents Design of heterocyclic small‑molecule modulators for nuclear receptors and bromodomains | — |
| 8 | Clinical Microbiomics Provider of meta-genomics platform and services | $10M | 47 mo ago | 26 | — | Series A | WordPressMySQLPHP+19 | — | — |
| 9 | Cysbio Manufacturer of amino acids & sulfated biochemicals | $9M | 45 mo ago | 15 | Hemanshu Mundhada Co-founder and Director | Seed | — | — | — |
| 10 | Fuse Vectors Provider of scalable gene therapy manufacturing platform | $5M | 18 mo ago | 3 | Benjamin Blaha Chief Technology Officer | Seed | Wix eCommerceWixSentry+12 | 2 patents In‑vitro manufacturing of parvovirus capsids for viral vector gene‑therapy production | — |
| 11 | 2cureX Provider of in-vitro tests for precision medicines | $5M | 67 mo ago | 4 | — | Funding Raised | WordPressMySQLPHP+16 | 13 patents Predictive biomarkers for colon cancer therapy response and phenotypic drug screening. | — |
| 12 | AthGene Personal genetic testing service | $3M | 113 mo ago | 17 | Yusufa Sey Co-Founder & CEO | Deadpooled | — | — | — |
| 13 | Twelve Bio Developer of CRISPER technology based diagnostics and therapeutics | $3M | 71 mo ago | 10 | Stefano Stella Co-Founder & CEO | Acquired | — | — | — |
| 14 | ExpreS2ion Biotechnologies Provider of recombinant protein production using an insect expression platform | $2M | 77 mo ago | 32 | — | Public | WordPressMySQLPHP+20 | 35 patents Engineering recombinant proteins with human-like, xylosylated N‑glycans for vaccine/therapeutic use | — |
| 15 | PixieGene Provider of a genetically modified porcine models for research for degenerative aging disorders | $2M | 114 mo ago | — | Kaj Vestergaard CEO | Deadpooled | — | — | — |
| 16 | Anapa Biotech Molecular tools to enhance the nucleic acids in PCR-based assays | $1M | 235 mo ago | 1 | Soren Echwald Owner & CEO | Series A | — | 7 patents Multiplex nucleic acid detection assays employing dual‑fluorescence quenching technology. | — |
| 17 | COBO Technologies Manufacturer of products for genome editing | $270K | 88 mo ago | 2 | Jens Ole Bock Co-Founder & CEO | Seed | — | — | — |
| 18 | FermBiotics Developed fermented plant ingredients for improving gut health | $200K | 94 mo ago | — | Soren Kjaerulff CEO | Funding Raised | — | — | — |
Top 12 Genomics companies in Capital Region of Denmark
#1
Series B · Copenhagen, Capital Region of Denmark · founded 2011 · 48 employees$53.9Mraised▾
Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely. The company focuses on treating difficult conditions like multidrug-resistant infections, cystic fibrosis, IBD, and certain cancers by engineering the human microbiome.
- Aug 2025Series B$40.6M
- Dec 2024Venture Debt$21.1M
- Jan 2024Series B$11.9M
- Jun 2022Series A$8.4M
#2
Seed · Copenhagen, Capital Region of Denmark · founded 2022 · 3 employees$5.2Mraised▾
Provider of scalable gene therapy manufacturing platform. The technology utilizes a cell-free AAV filling platform that enables the production of gene therapies at a larger scale for multiple diseases.
- Feb 2025Seed$5.2M
#3
Series B · Copenhagen, Capital Region of Denmark · founded 2001 · 9 employees$28.4Mraised▾
Developer of biomarkers and diagnostic kits. The company has developed an ELISA-based suPAR (soluble urokinase Plasminogen Activator Receptor) test. The company's product portfolio consists of three CE-IVD approved products such as the ELISA Standard kit for clinical research and the ELISA Flex kit for routine use at central laboratories and the suPARnostic Quick Triage test based on lateral flow technology provides results in 20 minutes.
- Jul 2022Grant (prize money)$51.1K
- Aug 2020Grant (prize money)$1M
- May 2020Series B$1.5M
- Jun 2018Series B$11.7M
#4
Series A · Birkerod, Capital Region of Denmark · founded 2013 · 26 employees$12.8Mraised▾
Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells. The company has developed a microfluidics instrument called Xdrop that encapsulates the target living cells, DNA fragments, or organelles together with the assay chemistry is highly stable double-emulsion droplets. It has applications for cell reaction screening and verification of gene edits.
- Mar 2023Grant (prize money)—
- Apr 2021Grant (prize money)$60.6K
- Dec 2020Series A$6.6M
- May 2019Grant (prize money)$2.1M
#5
Acquired · Copenhagen, Capital Region of Denmark · founded 2003 · 60 employees$104.3Mraised▾
Developer of RNA-targeted therapies for infectious and metabolic diseases. The company uses the proprietary Locked Nucleic Acid (LNA) platform and drug discovery platform to develop therapeutics with a focus on infectious diseases and cardiometabolic disorders. Its lead candidate is miravirsen (SPC3649), a short modified RNA molecule for the treatment of hepatitis C infections.
- 2012Series C$12M
- Jan 2011Series C$14M
- May 2008Grant (prize money)$9M
- Dec 2007Series B$30M
#6
Seed · Kongens Lyngby, Capital Region of Denmark · founded 2019 · 15 employees$9.2Mraised▾
Manufacturer of amino acids & sulfated biochemicals
- Nov 2022Grant (prize money)$51.8K
- Dec 2020Grant (prize money)$2.5M
- Oct 2020Seed$2.9M
- Oct 2020Grant (prize money)$1.4M
#7
Series A · Horsholm, Capital Region of Denmark · founded 2016 · 26 employees$9.7Mraised▾
Provider of meta-genomics platform and services. The company offers a comprehensive portfolio of services for microbiome studies such as Kits supply, Sample storage, metagenomics, transcriptomics, specialized microbiome characterization (e.g. real-time qPCR and strain type analysis), bioinformatics, and statistical analysis. It also provides customized sequencing solutions based on a particular project.
- Oct 2022Series A$9.7M
- Jan 2021Grant (prize money)$364.9K
- Sep 2020Grant (prize money)$354.7K
- Sep 2018Grant (prize money)$345.7K
#8
Acquired · Vedbaek, Capital Region of Denmark · founded 1995 · 65 employees$22.9Mraised▾
Exiqon develops LNA-based (Locked Nucleic Acid) tools for diagnostics and research. It has two major business units: Life Science and Diagnostics. Exiqon Life Sciences develops LNA-based kits for research use. Exiqon Diagnostics uses LNA-based tools for biomarker detection and the development of novel molecular diagnostic tests. In April 2016, Qiagen acquired Exiqon for $103M.
- Nov 2015Conventional Debt$40M
- Jun 2005Series B$19.7M
- Dec 2003Series A$3.2M
#9
Deadpooled · Copenhagen, Capital Region of Denmark · founded 2014 · 35 employees$14.1Mraised▾
Developer of a next-generation diagnostics platform to diagnose infectious diseases. The product includes BluBox which is a portable IVD device for single-drop-of-blood diagnostics for dengue and the COVID-19 and another device ViroTrack for virus identification. It is based on centrifugal microfluidics technology, magnetic nanoparticle physics, and Blu-Ray optics.
#10
Funding Raised · Copenhagen, Capital Region of Denmark · founded 2005 · 4 employees$4.6Mraised▾
Provider of in-vitro tests for precision medicines. The company's product IndiTreat sensitivity test helps in determining drugs and drug combinations on microtumors to identify resistance, sensitivity, and determining the effective treatment of colon cancer. The company has its own 3D microtumors in cancer therapy selection.
- Feb 2021Grant (prize money)$488.9K
- Feb 2018Grant (prize money)$371.3K
- Feb 2018Grant (prize money)$3.7M
#11
Acquired · Copenhagen, Capital Region of Denmark · founded 2001 · 40 employees$12.5Mraised▾
Developer of drug treatments for oncology and chronic inflammatory diseases. The Chemics technology involves the synthesis of the Chemetics molecule (Drug + DNA tag + Linker), high throughput screening for active compounds and finally optimization after the hit to lead stage.
- Jun 2012Series B$12.5M
- Oct 2003Series B—
#12
Public · Copenhagen, Capital Region of Denmark · founded 2010 · 32 employees$2.1Mraised▾
Provider of recombinant protein production using an insect expression platform. The platform technology uses a non-viral Drosophila cell expression platform for protein production. The ExpreS2 kit allows customers to set up the ExpreS2 platform in-house. ExpreS2ion Biotech also partners with companies for the development of vaccines for breast cancer, coronavirus, and tropical diseases, such as malaria and chikungunya.
- Apr 2020Grant (prize money)$942.9K
- Dec 2019Grant (prize money)$285.6K
- Oct 2019Conventional Debt$814.7K
- Jan 2017Grant (prize money)$52.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Denmark
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 593 Denmark-affiliated papers.
- University of Copenhagen183
- Aarhus University121
- Technical University of Denmark118
- Novo Nordisk Foundation65
- Copenhagen University Hospital59
- Gene2→25
- Genome5→19
- DNA sequencing2→10
- Population1→8
- Metagenomics2→8
- Gene2→8
- Metagenomics1→5
- Microbiome1→5
- DNA sequencing2→5
- microRNA1→4
- Gene2→5
Where bioinformatics is researched across Denmark
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.